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• Objective: To compare the safety and efficacy of transcatheter aortic valve replacement (TAVR) 
to surgical aortic valve replacement (SAVR) in patients with severe symptomatic aortic stenosis 
at intermediate surgical risk.  
• Design: Systematic literature review.  
• Methods: Literature searches were done in PubMed and Scopus search engines using key terms: 
TAVR, trans-catheter aortic valve replacement, SAVR, surgical aortic valve replacement, severe 
aortic stenosis, and intermediate risk. Filters included primary research only. Inclusion criteria 
were articles which studied an intermediate risk patient population (STS-PROM 3-15%), primary 
research, and compared outcomes of TAVR and SAVR in patients with severe aortic stenosis 
requiring replacement.  
• Results: Two randomized control trials were identified (Reardon et al & Leon et al). One 
propensity matched retrospective cohort study was identified (Brennan et al).  
• Conclusion: The side effect profile for both TAVR and SAVR are very different. TAVR shows 
higher rates of major vascular complications, pacemaker implantation, and risk of valvular 
regurgitation while patients undergoing SAVR experience greater rates of blood loss, kidney 
injury, atrial fibrillation and longer stays in the hospital and ICU. In patients at intermediate risk 
for surgery, the decision to undergo TAVR or SAVR should be based on the individual patient’s 
desired outcome. Both procedures show improved quality of life however TAVR has less risk for 
serious intraoperative complication and reduced recovery time while SAVR shows greater 
efficacy with less frequent paravalvular regurgitation, need for reintervention and pacemaker 
implantation.  
Introduction:  
Aortic stenosis is a condition which affects up to 9.8% of the 80-89 year old patient population.1 
Stenosis of the aortic valve is most commonly caused in the US by a process of inflammation and 
eventual calcification of the aortic valve leaflets.2 Patients can be asymptomatic for a long period 
however once the non-compliant valve causes enough narrowing it can lead to increased outflow 
obstruction of the left ventricle and eventual left ventricular hypertrophy. Once patients become 
symptomatic, they commonly complain of dyspnea on exertion, angina and syncope.2 Valve 
replacement is a necessity at this point as rates of mortality are as high as 25% and average survival time 
only 2-3 years if left untreated.3 
Severe aortic stenosis is defined as aortic stenosis with a maximum aortic transvalvular velocity 
of ≥ 4 m/s with aortic valve area ≤ 1 cm2. Symptomatic aortic stenosis is defined as aortic stenosis which 
is causing cardiac symptoms including decreased exercise tolerance, dyspnea with exertion, anginal 
chest pain, syncope and heart failure.4  After the onset of cardiac symptoms, the prognosis for severe 
aortic stenosis is very poor and has a high mortality rate.5 It is therefore recommended that all patients 
with severe aortic stenosis undergo aortic valve replacement.6,7  
Trans-catheter aortic valve replacement (TAVR) is a relatively new procedure which has been 
shown to have comparable outcomes and decreased rates of complications compared to surgical aortic 
valve replacement (SAVR) in patients considered to be at high surgical risk.8-10 TAVR is less invasive than 
surgical valve replacement as a catheter is placed percutaneously either through the femoral artery or 
via trans-thoracic approach to the aorta where a new aortic valve is deployed.11 As compared to SAVR 
which requires median sternotomy with cardiac bypass.12 In 2017 the American Heart Association and 
American College of Cardiology updated guidelines so that both TAVR and SAVR were equally acceptable 
options for aortic valve replacement in high risk patients (class I).13 The standard of care for 
intermediate risk patients however is less clear. The guidelines recommend SAVR (class I) and offer 
consideration of TAVR (Class IIa).13 The aim of our study is to examine available research to determine if 
TAVR is non-inferior to SAVR in terms of primary outcomes including death from any cause, disabling 
stroke or serious complications in intermediate risk patients.  
Case:  
Mr. J is a 75 year old male, whom you have followed in your practice for many years. He is a 
generally healthy adult male with a PMHx of HTN, HLD and mild aortic stenosis which has up to this 
point been asymptomatic. Recently Mr. J came to the clinic complaining of increasing exertional 
dyspnea as well as chest pain that worsens with activity. Transthoracic echocardiogram was performed 
and revealed a left ventricular ejection fraction of 40% indicative of left ventricular dysfunction likely 
due to progression of aortic valve stenosis. Aortic transvalvular velocity is determined to be 4 m/s with 
aortic valve area of 1 cm2 and mean transvalvular pressure gradient of 40 mmHg.  Mr. J will require 
aortic valve replacement to reduce symptoms and prevent progression of heart failure. He states that 
his father had his aortic valve replaced surgically years ago and died in the hospital “from 
complications”. He has heard that there is now a less invasive option called the trans-catheter aortic 
valve replacement (TAVR) procedure and is wondering if he would be a candidate for this procedure 
instead of surgery. This scenario poses the clinical question in adult male patients who present an 
intermediate surgical risk, does TAVR provide comparable clinical outcomes as surgical valve 
replacement in patients with severe aortic stenosis. 
Methods:  
A literature search was conducted on PubMed and Scopus search engines in September 2019. 
Key search terms included TAVR, trans-catheter aortic valve replacement, SAVR, surgical aortic valve 
replacement, severe aortic stenosis, and intermediate risk. This search yielded 376 results. These results 
were further filtered to include only primary research, excluding meta-analyses and systematic reviews. 
This resulted in 20 articles which were screened for inclusion or exclusion. Examination of the literature 
determined that most studies defined surgical risk with consideration of the Society of Thoracic 
Surgeons Predicted Risk of Mortality (STS-PROM) scoring system. Studies which did not utilize this 
scoring system were excluded to promote homogeneity of the included studies. Patient populations 
defined to be at high risk included those with risk of death within 30 days after surgery of ≥ 15%8 and 
populations at low risk were determined to have risk of death <3% within 30 days after surgery.14,15 
Studies with predominantly low or high surgical risk patient populations were excluded. The final 3 
selected articles met inclusion criteria of intermediate risk patient population (STS-PROM score 3-15%), 
primary research, and with the purpose of comparing outcomes between TAVR and SAVR procedures in 
patients with severe, symptomatic aortic stenosis requiring replacement. 
Results:  
Study #1:  
Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. Reardon et al.16 
Objective: To compare the safety and efficacy of TAVR with surgical aortic valve replacement in 
patients with severe, symptomatic aortic stenosis at intermediate surgical risk 
Study design: Patients were recruited from 87 centers in the United States, United Kingdom, 
Switzerland, Spain, Germany and Denmark. They underwent randomization in a 1:1 ratio to either 
receive TAVR or SAVR. Inclusion criteria are listed in Table 1. Most notably, they include an estimated 
risk of surgical death within 30 days between 3 and 15%. This risk was calculated using criteria from the 
Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) as well as the presence of co-
existing illness, frailty and disability.  Patients were considered to be eligible if they had severe aortic 
stenosis, defined as the presence of any of the criteria listed in Table 2. Inclusion in the study also 
required that patients be symptomatic due to their aortic stenosis, this was determined by requiring the 
patients be classified as New York Heart Association Class II or greater. Exclusion criteria are extensive 
and listed in the supplementary appendix available with the original article on the New England Journal 
of Medicine website (Table S3).  
Table 1: Inclusion Criteria 
STS PROM score ≥3% and < 15%  
Eligible for both TAVR and SAVR  
Presence of severe aortic stenosis  
Subject is symptomatic: NYHA Functional Class II 
or greater  
Subject and physician agree to required follow up  
Subject meets legal minimum age to provide 
informed consent  
 
Table 2: Criteria used to determine the presence of severe aortic stenosis  
Initial aortic valve area of ≤ 1 cm2          
Aortic valve area index of < 0.6 cm2 per square meter of body surface area and a mean 
gradient of > 40 mm Hg  
Maximum aortic velocity of > 4 m/s at rest or with dobutamine provocation in patients with 
LVEF < 55%  
Doppler velocity index of < 0.25 on resting echocardiogram    
 
 
Patients were randomized at each clinical site considering the need for coronary 
revascularization as determined by the multi-disciplinary heart team at each location. Patients in the 
surgical group underwent coronary revascularization at the time of aortic valve replacement. The 
majority of patients in the TAVR group underwent transfemoral access. Subclavian or direct aortic 
approach was only utilized in patients who had iliofemoral anatomy which prohibited femoral access. 
Post-operatively, patients in the surgical group received 81 mg of aspirin daily while patients in the TAVR 
group received dual antiplatelet therapy with 81-100 mg of aspirin in combination with 75 mg of 
Clopidogrel for 3 months following the procedure.  
Primary end points included death from any cause or disabling stroke at 24 months. Each 
patient was evaluated by a trained neurologist or stroke specialist to determine this. All neurological 
events were reported and evaluated by a neurologist on the clinical events committee. Secondary end 
points included cardiovascular events such as myocardial infarction, cerebrovascular events such as TIA 
or CVA, as well as any need for re-intervention. Serial echocardiograms were completed at an 
independent laboratory to measure aortic valve hemodynamics following the procedure through 24 
months. Health related quality of life assessments were also evaluated through 24 months.  
Bayesian statistical methods were used to compare outcomes in the TAVR and SAVR groups. The 
primary and secondary endpoints were evaluated using a modified intention to treat population. To 
account for missing data (lost to follow up or patients who had withdrawn from the study), a sensitivity 
analysis was performed. Bayesian analogue of a two sample t-test was used to compare continuous 
variables as means. Categorical variables were compared as frequencies and percentages using a 
Bayesian version of comparison proportions. Event rates are given as Bayesian posterior medians with 
95% credible intervals. Kaplan Meier survival analyses were also performed.  
Results: Between June 19, 2012 and June 30, 2016 1746 patients underwent randomization. The 
modified intention to treat population included 1660 patients. 864 patients were assigned to undergo 
TAVR procedure and 796 to surgical valve replacement. The mean age of the patients in the study was 
79.8 ± 6.2 years. All patients were considered to be at intermediate surgical risk with the mean STS 
PROM score 4.5 ± 1.6%.  
Differences in procedural outcomes showed an increased risk of acute kidney injury, new or 
worsening atrial fibrillation, and need for blood transfusion in the surgical group while the TAVR group 
showed an increased risk of major vascular complications and required pacemaker implantation. Major 
vascular complications are listed in Table S4 of the supplementary appendix and include complications 
such as aortic dissection, new apical aneurysm, access site or access related vascular injury (dissection, 
stenosis perforation, hematoma, etc.), non-cerebral distal embolization, and new ipsilateral lower 





At 24 months, the primary endpoint (composite of death from any cause and stroke) was similar 
between TAVR (12.6%) and SAVR (14.0%) groups. In the intention to treat population, similar results 
were found (13.2% in the TAVR group and 14.1% in the SAVR group). The rate of death from any cause 
(TAVR 11.4% vs. SAVR 11.6%) as well as disabling stroke (TAVR 2.6% vs. SAVR 4.5% with 95% CI -4.0,0.1) 
were also similar in both groups at 24 months. There is no significant difference in other outcomes 
assessed, all of which are presented in Table 4. Both groups also showed significant improvement in 
NYHA symptoms throughout the 24 month follow up period. Echocardiographic findings showed 
improved hemodynamics in both the TAVR and SAVR groups. Paravalvular regurgitation however was 
more prevalent in the TAVR group (5.3%) than the SAVR group (0.6%). Whether the incidence of 
paravalvular regurgitation was clinically significant requiring reintervention was not reported however 
TAVR showed a significantly elevated requirement for valve reintervention (2.8% vs 0.7%) as well as 
hospitalization for valve related disease (13.2% vs 9.7%) when compared to the SAVR group.  
 




Study Critique: Strengths of this study include that it is a randomized control trial with a large 
patient population. Weaknesses include the fact that this study was not only funded by Medtronic, the 
company that produces the prosthesis used in the TAVR procedure, but the protocol was developed by 
representatives of Medtronic and the sites where patients were recruited from were chosen by 
representatives of Medtronic. Medtronic was also responsible for monitoring data collection and 
management of the trial. This presents a clear conflict of interest in which a favorable outcome of the 
study directly benefits those who funded the study. It is also unclear from the article how the need for 
revascularization affected placement in either TAVR or SAVR groups. The article states that the need for 
revascularization was considered which would then impair randomization if certain patient 
characteristics determined which group the patient was assigned to. This may improve outcomes in the 
TAVR group if patients who required revascularization were placed into the SAVR group exclusively.  
Another issue with the study is that two different prosthetic valves were utilized in the TAVR 
procedures, however the study did not present data for the TAVR group that stratified results by valve 
type. Additionally, the study did not stratify results by TAVR route, i.e. transthoracic or transfemoral, 
only offering combined data from both routes. Aggregating these results could artificially inflate the 
Table 4: Clinical Outcomes at 30 days, 12 months, and 24 months (Modified Intention To Treat 
Population)*16 
safety of the TAVR procedure, as one access route or valve type may have had poorer outcomes than 
others, but this is masked in the combining of the data.  
Study #2: 
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. Leon et al.17 
Objective: To compare the safety and efficacy of TAVR to SAVR in the treatment of severe, 
symptomatic aortic stenosis in patients considered to be at intermediate surgical risk.  
Methods: Patients were selected from 57 centers in the United States and Canada. Inclusion 
criteria were the presence of severe aortic stenosis as well as cardiac symptoms. Intermediate risk was 
defined as an STS PROM score between 4% and 8% however patients could be included in the study if 
they had an STS PROM score of < 4% and any comorbidities not accounted for in the STS risk model. The 
SAPIEN XT heart valve was used for all TAVR procedures. Patients in the TAVR group underwent either 
trans-femoral or trans-thoracic (transapical or transaortic) placement of the SAPIEN valve. All patients in 
the TAVR group received ASA 81 mg and clopidogrel 300 mg prior to the procedure and heparin intra-
operatively. ASA was continued indefinitely and clopidogrel for a minimum of 1 month in TAVR patients. 
Prior to randomization, all subjects underwent peripheral arterial evaluation to determine which 
patients would require trans-thoracic as opposed to trans-femoral TAVR approach. These patients were 
stratified into separate groups (eligible for transfemoral or transthoracic) and then randomized in a 1:1 
fashion to the surgical or TAVR group to ensure equal distribution. Intention to treat analysis was used 
to evaluate primary and secondary endpoints. The primary endpoint evaluated was a composite of 
death from any cause or disabling stroke at 2 years. All patients were evaluated by a trained neurologist 
and any neurological event which occurred was evaluated by a neurologist who was blinded to which 
procedure the patient received.  
Fisher’s exact test was used to compare categorical variables. Continuous variables were 
compared using Student’s t-test or Wilcoxon rank-sum test. Kaplan-Meier estimates were used to 
calculate time to event analyses. Hazard ratios were calculated to evaluate the relationship between 
subgroups and outcomes of interest.  
2032 patients underwent randomization with 1011 assigned to the TAVR group and 1021 
assigned to surgery. 236 patients in the TAVR group underwent transthoracic as opposed to 
transfemoral valve placement. The mean STS PROM score was 5.8% in both the TAVR and SAVR groups.  
Results: Evaluation of the primary endpoint of death from any cause or disabling stroke at 2 
years showed no statistically significant difference between the TAVR and SAVR cohorts (HR 0.89; 95% CI 
0.73, 1.09, p = 0.25). Patients who were treated via trans-femoral access in the TAVR group showed a 
lower rate of death from any cause or disabling stroke than those in the SAVR cohort (HR 0.79; 95% CI 
0.62-1.00; p = 0.05) while there was no difference in the rate of these outcomes seen in those who were 
treated via transthoracic access and those treated surgically (HR 1.21; 95% CI 0.84, 1.74, p = 0.47).  
Treatment with TAVR showed an increased risk of major vascular complications at 30 days (7.9% 
vs. 5.0%, p = 0.008). Major vascular complications are listed in Table S2 of the supplementary appendix 
and include complications such as aortic dissection, new apical aneurysm, access site or access related 
vascular injury (dissection, stenosis perforation, hematoma, etc.), non-cerebral distal embolization, and 
new ipsilateral lower extremity ischemia. Life threatening bleeding (10.4% vs. 43.4%, p<0.001), acute 
kidney injury (1.3% vs. 3.1%, p = 0.006) and new onset atrial fibrillation (9.1% vs. 26.4%, p < 0.001) were 
all significantly increased in those undergoing surgical intervention. There was no significant difference 
in repeat hospitalizations (19.6% and 17.3%, p = 0.22) or rate of valvular reintervention (1.4% vs. 0.6%, p 
= 0.09) between TAVR and SAVR groups at 2 years. The TAVR cohort had a significantly reduced duration 
of stay in the ICU (median 2 vs. 4 days, p < 0.001) and hospital (6 vs. 9 days, p < 0.001) compared to the 
SAVR cohort. 
Both groups showed significant reduction in NYHA Class following treatment (p<0.001 for all 
comparisons).  Echocardiographic findings common to both cohorts include improved ejection fraction, 
increased aortic valve areas and decreased aortic valve gradients. TAVR however showed superior 
improvement over SAVR in aortic valve area and gradient. Patients who underwent TAVR showed a 
statistically significant increased frequency and severity of aortic regurgitation when compared to SAVR 
(Figure 1). Patients who had moderate or severe paravalvular aortic regurgitation at 30 days had a 
higher mortality rate (Figure 2) during the 2 year follow up period than patients without regurgitation 








Figure 1: Percentage of Patients with paravalvular aortic regurgitation 17 
Figure 2: Death from Any Cause, According to Severity of Paravalvular Aortic Regurgitation17 
 
Critique: Strengths of this study include that it is a randomized control trial that is well powered 
with a large sample size. The study design was unique in the pre-operative evaluation of peripheral 
arteries and randomization process considering transfemoral and transthoracic approach. Blinding of 
neurologists who evaluated possible strokes was another advantage of the study design.  
Weaknesses include that the study was funded by Edwards Life Sciences and only utilized the 
valve type which the company produced. The study sites, methods and data collection were all chosen 
and overseen by Edwards Life Sciences. This presents a significant conflict of interest.  
Study #3:  
Transcatheter versus Surgical Aortic Valve Replacement: A Propensity-Matched Analysis from Two 
United States Registries. Brennan et al. 14 
Objective: The objective of this study was to compare the safety and efficacy of TAVR and SAVR 
in a large patient population thought to be more representative of the average patient than those 
included in previously conducted randomized control trials.  
Study Design: This was a propensity matched retrospective cohort study which reviewed 
Medicare insurance claims of patients who had either undergone SAVR or TAVR. SAVR data was 
collected from the society of thoracic surgeons (STS) national database. More than 90% of cardiac 
surgery programs in the US participate in this database. TAVR data was collected from the STS/American 
College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) registry. Participation in this registry is 
required for Medicare reimbursement in the U.S. Records identified from these databases were then 
linked to the Centers for Medicare & Medicaid Services (CMS) fee-for-service administrative insurance 
claims files in order to create a chronological record of events including vital status and any 
rehospitalization occurrences. 25,786 records were available from TAVR cases performed between 
January 1, 2014 and September 30, 2015 while 198,077 SAVR records were available for cases 
performed between July 1, 2011 and December 31, 2013. Patients included in the study were older 
patients with severe, symptomatic aortic valve stenosis who were considered to be at intermediate or 
high surgical risk, were candidates for both TAVR and SAVR and who eventually underwent either TAVR 
or SAVR. Exclusion criteria included patient characteristics that would seem to favor one treatment 
strategy over the other. These criteria are listed in Table 5.  
Table 5: Exclusion Criteria – Brennan et al. 
• Patient age < 65 or > 90  
• Other major cardiac operations  
• History of endocarditis 
• Emergency salvage status  
• Primary aortic insufficiency  
• Hostile chest or porcelain aorta 
• Moderate to severe mitral stenosis  
• STS-PROM < 3%  
• Subsequent aortic valve replacement procedures during the initial aortic valve replacement 
admission  
• Hospitals submitting < 10 total SAVR or TAVR records during the study interval  
 
Primary outcomes which were assessed were decided through consensus by a panel of patients, 
caregivers, clinicians, health science researchers and statisticians. These outcomes included: death, 
stroke, days alive out of acute care hospital facility (DAOH) to 1 year as well as discharge to home. 
Stroke and mortality were evaluated to 30 days and 1 year.  
Propensity score matching was conducted to balance the covariates between the SAVR and 
TAVR groups. Propensity score was defined as the probability of receiving TAVR given measured 
covariates. These were calculated using logistic regression. Covariates were defined as patient 
characteristics which would favor one treatment plan over the other and they were identified by the 
expert panel mentioned previously. Distribution of covariates between the study groups were assessed 
and patients who fell under 5% or over 95% of propensity distribution were excluded due to 
overwhelming likelihood of receiving one treatment over the other. Propensity score matching was 
completed in a 1:1 ratio by greedy matching using a caliper of 0.2 standard deviations.  
COX proportional hazard models were used to compare outcomes in the TAVR and SAVR groups 
by hazard ratios (HRs) with 95% confidence intervals (CIs). DOAH was modeled as count data using 
generalized estimating equations with a long link and fixed offset to obtain rate ratios (RRs) with 95% CI. 
Statistical significance was defined as p < 0.1. All analyses were conducted using SAS version 9.4 (SAS 
Institute, Inc., Cary, NC).  
Results: The propensity matched cohorts included 4,732 SAVR patients and 4,732 TAVR patients. 
The median age was 82 years (interquartile range (IQR): 77, 85), 47.9% women and median STS PROM of 
5.6% (4.2%, 8.2%). Transfemoral access was utilized in 76% of TAVR patients with 33% utilizing the 
CoreValve prosthesis (Medtronic) and 67% utilizing the SAPIEN valve prosthesis (Edwards LifeSciences).  
During the initial visit, TAVR patients spent an average of 31 (IQR: 24, 57) hours in the intensive 
care unit (ICU) and 4 (IQR 3,6) days in the hospital while SAVR patients spent an average of 68 (IQR: 37, 
119) hours in the ICU and 8 (IQR: 6, 11) days in the hospital. In hospital mortality was found to be lower 
in patients who received TAVR than SAVR (3.0% vs. 5.0%, p<0.001) with no significant difference in the 
incidence of stroke (2.5% vs. 2.7%, p=0.4). TAVR patients showed an increased incidence of new 
pacemaker/implantable cardioverter defibrillator placement (12.8% vs. 6.3%, p < 0.001) as well as a 
higher rate of major vascular complications (4.2% vs. 0.4%, p< 0.001). TAVR patients did show a lower 
incidence of blood transfusions (packed red blood cell units: TAVR 0 [0,0], SAVR 2 [0,4], p<0.001) as well 
as a decreased requirement for hemodialysis following the procedure (1.7% vs. 3.2%, p,0.001) during 
the initial hospitalization. TAVR patients had a higher rate of discharge to home (69.9% vs. 41.2%) while 
those who received SAVR were more likely to be discharged to an extended care facility, transitional 
care unit, or rehabilitation unit (41.2% vs. 20.5%, p < 0.01).  
There was no difference in mortality at 1 year between TAVR and SAVR cohorts (17.3% vs. 
17.9%, p=0.40), stroke during the first 30 days (2.8% vs. 2.8%, p = 0.13) or at 1 year (HR 1.18 95% CI 
0.95-1.47). Days alive out of hospital (DAOH) were similar between TAVR and SAVR groups (RR 1.0, 95% 
CI 0.98-1.02).  
A stratified analysis was performed looking at key outcomes at 1 year including death, stroke, 
discharge to home and DAOH in subgroups determined by STS PROM scores: 3-5%, 5-8%, ≥ 8%. There 
was no significant difference in these key outcomes based on treatment strategy (TAVR or SAVR). The 








Study Critique: Strengths of this study include its large sample size of 9,464 patients, that it is 
independently funded by the Patient Centered Outcomes Research Institute (PCORI) award, and that it 
includes both the Edwards LifeSciences and Medtronic valve prostheses. The fact that records were 
linked to Medicare insurance claims allowed for creation of a chronological log of events and ensured 
inclusion of the patient population most commonly affected by aortic stenosis (> 65 years). Propensity 
matching allowed for even distribution of potential cofounding variables between the TAVR and SAVR 
groups. Weaknesses of this study include that it was a retrospective cohort study that is not 
randomized. Additionally, different time frames were utilized for TAVR (2014-2015) and SAVR cases 
(2011-2013) however this is unlikely to significantly alter results as significant changes in SAVR are 
unlikely to have occurred during this period. Certain exclusion criteria may have altered results including 
exclusion of cases requiring subsequent aortic valve replacement procedures during the initial valve 
replacement admission. Exclusion of these cases may have ignored cases in which TAVR procedure was 
ineffective and required surgical replacement. Exclusion of hospitals submitting < 10 total SAVR or TAVR 
records during the study interval may have altered results by only examining high volume centers with 
interventional cardiologists who have a high level of expertise in the TAVR procedure.  
Discussion:  
The first two studies (Reardon et al, Leon et al) were very similar in the outcomes they assessed 
and study design. They were also both funded by the companies responsible for producing the 
prosthetic valve used in the TAVR procedure. This represents a definite conflict of interest however 
Table 6: Clinical Outcomes to 1 Year, Stratified by Surgical Risk (STS PROM) 14 
given the novelty of the procedure there are not any randomized control trials we could find that were 
not funded by medical device companies which focused on an intermediate surgical risk patient 
population. Both studies had similar findings which showed better immediate outcomes and less serious 
complications associated with the TAVR procedure when compared to SAVR. They both showed a 
reduced risk of acute kidney injury, serious bleeding as well as new onset or worsening atrial fibrillation 
with the TAVR procedure. Patients who underwent TAVR also spent less time in the ICU and the hospital 
than patients who underwent SAVR. Where the TAVR procedure was inferior to SAVR in the immediate 
post-operative period was an increased incidence of major vascular complications and requirement for 
pacemaker or defibrillator implantation. Both studies also compared outcomes at 2 years. Most of these 
showed TAVR to be non-inferior to SAVR including composite incidence of death and stroke, all-cause 
mortality, stroke alone, as well as improved quality of life as measured by NYHA classification. Key 
differences at 2 years include an increased rate of required re-intervention, re-hospitalization as well as 
paravalvular regurgitation in patients who underwent the TAVR procedure.  
The third study which was included (Brennan et al) was different than the first two in that it was 
not a randomized control trial. This study was designed as a retrospective cohort which had a large 
sample size and linked patients records to the Medicare & Medicaid fee for service database in order to 
create a chronological record of events in patients who had received either TAVR or SAVR. Benefits of 
this study include that it was funded by an independent educational grant and not a medical device 
company. It included both the Medtronic and Edwards LifeSciences devices which reduced likelihood for 
bias. This study supported findings of the previous two including increased risk of blood loss as well as 
time spent in the ICU and hospital following SAVR as well as increased rate of major vascular 
complications and required pacemaker implantation in patients who underwent TAVR. It also found that 
the rate of mortality, stroke and days alive out of hospital (DAOH) were unaffected by SAVR or TAVR 
procedure. Additional findings of this study which were not reported in the previous two included 
increased rate of hemodialysis and in hospital mortality in patients who underwent SAVR.   
Conclusion: 
Overall, the studies show a similar rate of long-term efficacy and complications between TAVR 
and SAVR, with similar rates of all-cause mortality and stroke as far as 24 months as well as an improved 
quality of life following both procedures. The side effect profile for each is different, with patients 
undergoing SAVR experiencing greater rates of blood loss, kidney injury, new onset or worsening atrial 
fibrillation and longer stays in the hospital or ICU. TAVR patients however experience greater rates of 
major vascular complications, pacemaker implantation, and significantly increased risk of valvular 
regurgitation requiring re-intervention.  
Given the significant side effects of both TAVR and SAVR and the relative lack of available 
research conducted in intermediate risk patients, it’s difficult to suggest one treatment option over the 
other. The choice would depend on the patient and what outcome they desire. If it is a younger patient 
with fewer comorbidities, SAVR would likely be the better option due to less frequent need for re-
intervention and regurgitation. However, if it were an older patient who only wishes to improve quality 
of life for a few more years, TAVR would be a superior option due to less recovery time and serious 
intraoperative risks.  
Case Resolution:   
Mr. J is a 75-year-old male with past medical history of hypertension and hyperlipidemia who 
has just recently progressed to severe aortic stenosis requiring intervention. He is younger than the 
average age of the patient population included in all three studies and has relatively few comorbidities. 
At this point the recommended intervention for this patient would be surgical aortic valve replacement 
(SAVR). If the patient were resistant to surgical intervention, TAVR could be considered however it 
should be explained to the patient that although TAVR has less immediate post-operative complications 
and shorter recovery it does increase risk for required reintervention at a later point in time. Therefore, 
SAVR would provide a better chance at definitive treatment of his severe aortic stenosis.   
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